Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 5Neoplasms 3Ovarian Neoplasms 2Solid Tumors 1Solid Cancers 1Prostatic Neoplasms, Castration-Resistant 1Prostatic Neoplasms 1Oropharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma 1

Interventions

enzalutamide 4darolutamide 2xentuzumab 1olaparib 1ipatasertib 1ibrutinib 1gallium 68 PSMA-11 1atezolizumab 1apalutamide 1TVB-2640 1Rosuvastatin Calcium 1Pioglitazone 1JNJ-64619178 1JNJ-64264681 1Docetaxel 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Prostatic Neoplasms, Castration-Resistant × ipatasertib × Clear all
NCT04404140 2023-10-17

A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Hoffmann-La Roche

Phase 1 Terminated
6 enrolled
Genitourinary

Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡